CD8A and neoplasm: We next sought to further dissect the profile of CD8+ T-cells with a focus on distinct tumor-controlling subtypes, including tissue-resident memory T-cells (TRM) (16), tumor-reactive CD8+ T-cells (17), and antigen-specific T-cells (18) which have been reported to contribute to the success of cancer immunotherapy.